Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of 1,6-diphosphofructose phosphatase for preventing and treating parkinsonism

A technology of fructose diphosphate and syndrome, applied in the field of pharmacy, can solve the problems of relapse, weakened drug effect, failure to prevent or slow down the development of the disease, etc.

Inactive Publication Date: 2010-06-09
连晓媛
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

3) Amantadine and dihexyphenidyl; amantadine can partially improve the symptoms of Parkinson's syndrome, but the mechanism of action is not very clear; It has a certain therapeutic effect, but it causes more obvious side effects of mental retardation
[0004] To Parkinson's syndrome, above-mentioned three classes of medicines not only can only treat symptoms, but also have great limitations: 1) these medicines can only alleviate symptoms, and medicine must be taken for a long time, once stopping treatment, the state of an illness will recur; Medication wears off, usually after 3-5 years of treatment and becomes unmanageable
2) Not only cannot prevent or slow down the development of the disease, reverse the disease, but also promote the disease
Quite a number of foreign studies have proved that levodopa can produce neurotoxicity, so this type of drug may aggravate dopamine nerve damage, thereby promoting the development of Parkinson's disease
3) The side effects of the drug are large, especially with the prolongation of the medication time, the side effects of the drug and its curative effect will offset the merits and demerits

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 1,6-diphosphofructose phosphatase for preventing and treating parkinsonism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 11、6- 2

[0043] Embodiment 11, 6-diphosphate fructose, succinic acid, glutamine prevent Parkinson's syndrome

[0044] method:

[0045] Model preparation and exercise behavior observation: adult male wistar rats (210-230g) were subcutaneously injected with rotenone (dissolved in a 1:25 mixed vehicle containing DMSO and sunflower oil) at a dose of 1mg / kg (1ml / kg / day) , injected twice a day, each injection 0.5mg / kg, continuous monitoring of animal movement behavior and body weight changes, until the animal can not stand up and walk limbs, difficulty turning over, loss of active eating ability to stop giving rotenone. Rotenone can cause weight loss in animals, and the more the weight loss, the more obvious the motor behavior defect. A small number of animals will develop tolerance to a certain dose of rotenone, manifested as weight gain. To overcome this tolerance phenomenon, the dose of Rotenone was increased by 20% when the animals showed weight gain for three consecutive days.

[0046...

Embodiment 21、6- 2

[0052] Embodiment 21, the combined application of fructose 6-diphosphate and succinic acid or glutamine to prevent Parkinson's syndrome method:

[0053] Rat Parkinson's syndrome modeling and motor behavior observation methods are the same as Example 1, and the model control group of Example 1 and the control group administered with fructose 1,6-diphosphate, succinic acid, and glutamine alone are used.

[0054] Drug prevention treatment: male wistar adult rats (210-230g) were randomly divided into two dosage groups of FBP and succinic acid combined (FBP 100mg / kg+succinic acid 50mg / kg and FBP 100mg / kg+succinic acid 100mg / kg, n= 5), FBP and glutamine (FBP100mg / kg+glutamine120mg / kg, ip, n=5) combined group. Animals in each group were injected intraperitoneally one hour before each administration of rotenone, and the body weight and movement behavior changes of the animals were continuously monitored until all animals in the model group lost motor function. Finally, the heart was p...

Embodiment 3

[0059] method:

[0060] Drug treatment: Male wistar adult rats (210-230g) were used to create a model of rotenone Parkinson's syndrome by the above method, that is, when the animals had limbs that could not stand, walk or turn over, or lost the ability to actively eat, they were randomly divided into natural recovery control groups. group (Rotenone, n=4) and fructose 1,6-diphosphate (FBP) treatment group (200 mg / kg, ip, n=5). FBP was given once a day, and the control group was given the same dose of normal saline until the motor behavior of animals in the FBP group returned to normal levels.

[0061] test results:

[0062] FBP has a significant therapeutic effect on rotenone-induced parkinsonism in rats. After 3 days of treatment with FBP, the symptoms of Parkinson's syndrome animals began to improve, manifested as exercise capacity and weight gain. After 2 weeks of treatment, the symptoms of Parkinson's syndrome disappeared, motor function returned to normal, and the body w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of independent 1,6-diphosphofructose phosphatase as well as application of the 1,6-diphosphofructose phosphatase and one or a plurality of compounds selected from succinic acid, glutamyl or unknown compounds for treating the parkinsonism in the prevention and treatment of the parkinsonism. Experiments prove that the 1,6-diphosphofructose phosphatase has very remarkable activity for preventing and treating the parkinsonism and can prevent the generation and the development of the parkinsonism and remarkably relive symptoms.

Description

technical field [0001] The invention relates to the field of pharmacy, especially the application of 1,6-diphosphate fructose and the combined application of 1,6-diphosphate fructose and other compounds. Background technique [0002] Parkinson's syndrome, also known as "parkinsonism", is a neurodegenerative disease common in middle-aged and elderly people, and it is also a worldwide difficult disease. The clinical symptoms mainly include: tremors in hands, feet or other parts of the body; Loss of flexibility, stiffness and sluggishness, often accompanied by other symptoms. The root cause of these symptoms is that the synthesis of dopamine decreases after pathological changes occur in the dopamine neurons located in the "substantia nigra" of the midbrain, resulting in a decrease in the function of dopamine inhibiting acetylcholine, and a relative increase in the excitatory effect of acetylcholine. However, the causes of dopamine neuropathological changes and death are divers...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7024A61K31/194A61K31/198A61P25/16
Inventor 连晓媛
Owner 连晓媛